Advertisement

Annals of Surgical Oncology

, Volume 24, Issue 11, pp 3116–3123 | Cite as

Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer

  • Charlotte Gamble
  • Laura J. Havrilesky
  • Evan R. Myers
  • Junzo P. Chino
  • Scott Hollenbeck
  • Jennifer K. Plichta
  • P. Kelly Marcom
  • E. Shelley Hwang
  • Noah D. Kauff
  • Rachel A. Greenup
Breast Oncology

Abstract

Background

The appropriate management of breast cancer risk in BRCA mutation carriers following ovarian cancer diagnosis remains unclear. We sought to determine the survival benefit and cost effectiveness of risk-reducing mastectomy (RRM) among women with BRCA1/2 mutations following stage II–IV ovarian cancer.

Design

We constructed a decision model from a third-party payer perspective to compare annual screening with magnetic resonance imaging (MRI) and mammography to annual screening followed by RRM with reconstruction following ovarian cancer diagnosis. Survival, overall costs, and cost effectiveness were determined by decade at diagnosis using 2015 US dollars. All inputs were obtained from the literature and public databases. Monte Carlo probabilistic sensitivity analysis was performed with a $100,000 willingness-to-pay threshold.

Results

The incremental cost-effectiveness ratio (ICER) per year of life saved (YLS) for RRM increased with age and BRCA2 mutation status, with greater survival benefit demonstrated in younger patients with BRCA1 mutations. RRM delayed 5 years in 40-year-old BRCA1 mutation carriers was associated with 5 months of life gained (ICER $72,739/YLS), and in 60-year-old BRCA2 mutation carriers was associated with 0.8 months of life gained (ICER $334,906/YLS). In all scenarios, $/YLS and mastectomies per breast cancer prevented were lowest with RRM performed 5–10 years after ovarian cancer diagnosis.

Conclusion

For most BRCA1/2 mutation carriers following ovarian cancer diagnosis, RRM performed within 5 years is not cost effective when compared with breast cancer screening. Imaging surveillance should be advocated during the first several years after ovarian cancer diagnosis, after which point the benefits of RRM can be considered based on patient age and BRCA mutation status.

References

  1. 1.
    Antoniou AC, Pharoah PDP, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86:76-83.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Chen S, Iversen ES, Friebel T, et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol. 2006;24(6):863-871.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    van der Kolk DM, de Bock GH, Leege BK, et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat. 2010;124:643-651.CrossRefPubMedGoogle Scholar
  4. 4.
    Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56(1):265-271.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346(21):1616-1622.CrossRefPubMedGoogle Scholar
  6. 6.
    Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women iwht a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346(21):1609-1615.CrossRefPubMedGoogle Scholar
  7. 7.
    Meijers-Heijboer H, van Geel B, van Putten WLJ, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159-164.CrossRefPubMedGoogle Scholar
  8. 8.
    Hartmann LC, Sellers TA, Shchaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93(21):1633-1637.CrossRefPubMedGoogle Scholar
  9. 9.
    National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. 2017. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 27 Feb 2017.
  10. 10.
    Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL. Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review. Am J Surg. 2016;212(4):660-669.CrossRefPubMedGoogle Scholar
  11. 11.
    George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14(5):284–296.CrossRefPubMedGoogle Scholar
  12. 12.
    Grann VR, Patel PR, Jacobson JS, et al. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat. 2011;125:837-847.CrossRefPubMedGoogle Scholar
  13. 13.
    Society of Gynecologic Oncology. SGO Clinical Practice Statement: Genetic Testing for Ovarian Cancer. Society of Gynecologic Oncology; 2014.Google Scholar
  14. 14.
    Howlander N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2012. Based on November 2014 SEER data submission, posted to the SEER web site, April 2015. http://seer.cancer.gov/csr/1975_2012/. Accessed 5 Jan 2016.
  15. 15.
    Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008;26(1):20-25.CrossRefPubMedGoogle Scholar
  16. 16.
    Alsop K, Fereday S, Meldrum C, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012;30(21):2654-2663.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Ledermann JA, Harter P, Gourley C, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579-1589.CrossRefPubMedGoogle Scholar
  18. 18.
    Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154-2164.CrossRefPubMedGoogle Scholar
  19. 19.
    Sander GD, Neumann PJ, Basu A, et al. Second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093-1103.CrossRefGoogle Scholar
  20. 20.
    Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797.CrossRefPubMedGoogle Scholar
  21. 21.
    Havrilesky LJ, Alvarez Secord A, Darcy KM, Armstrong DK, Kulasingam S. Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2008;26(25):4144-4150.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Heemskerk-Gerritsen BA, Menke-Pluijmers MB, Jager A, et al. Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis. Ann Oncol. 2013;24(8):2029-2035.CrossRefPubMedGoogle Scholar
  23. 23.
    Havrilesky LJ, Chino JP, Myers ER. How much is another randomized trial of lymph node dissection in endometrial cancer worth? A value of information analysis. Gynecol Oncol. 2013;131(1):140-146.CrossRefPubMedGoogle Scholar
  24. 24.
    Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity and gene mutator phenotype in patients with ovarian cancer. JAMA. 2011;306(14):1557-1565.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    van der Burg ME, Onstenk W, Boere IA, et al. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer. Eur J Cancer. 2014;50(15):2592-2601.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhong Q, Peng HL, Zhao X, Zhang L, Hwang WT. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clin Cancer Res. 2015;21(1):211-220.CrossRefPubMedGoogle Scholar
  27. 27.
    Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10-16.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lakhani SR, Van De Vijver MJ, Jacquemier J, et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol. 2002;20(9):2310-2318.CrossRefPubMedGoogle Scholar
  29. 29.
    Spurdle AB, Couch FJ, Parsons MT, et al. Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Res. 2014;16(6):1.CrossRefGoogle Scholar
  30. 30.
    Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429-4434.CrossRefPubMedGoogle Scholar
  31. 31.
    Arias E. United States Life Tables, 2011. Natl Vital Stat Rep. 2015;64(11):1–63.PubMedGoogle Scholar
  32. 32.
    Halfhill TR. Tom’s Inflation Calculator. 2016. http://www.halfhill.com/inflation_js.html. Accessed 23 May 2015.
  33. 33.
    Plevritis SK, Kurian AW, Sigal BM, et al. Cost-effectiveness of screening BRCA1/2 mutation carrierw with breast magnetic resonance imaging. JAMA. 2006;295:2374-2384.CrossRefPubMedGoogle Scholar
  34. 34.
    Zendejas B, Moriarty JP, O’Byrne J, Degnim AC, Farley DR, Boughey JC. Cost-effectiveness of contralateral prophylactic mastectomy versus routine surveillance in patients with unilateral breast cancer. J Clin Oncol. 2011;29(22):2993-3000.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Fitzpatrick AM, Gao LL, Smith BL, et al. Cost and outcome analysis of breast reconstruction paradigm shift. Ann Plast Surg. 2014;73(2):141-149.CrossRefPubMedGoogle Scholar
  36. 36.
    Mattos D, Gfrerer L, Reish RG, et al. Lifetime costs of prophylactic mastectomies and reconstruction versus surveillance. Plast Reconstr Surg. 2015;136(6):730e-740e.CrossRefPubMedGoogle Scholar
  37. 37.
    Yabroff KR, Lamont EB, Mariotto A, et al. Cost of care for elderly cancer patients in the United States. J Natl Cancer Inst. 2008;100(9):630-641.CrossRefPubMedGoogle Scholar
  38. 38.
    Vencken PM, Kriege M, Hooning M, et al. The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: implications for counseling. Cancer. 2013;119(5):955-962.CrossRefPubMedGoogle Scholar
  39. 39.
    Gangi A, Cass I, Paik D, et al. Breast cancer following ovarian cancer in brca mutation carriers. JAMA Surg. 2014;149(12):1306-1313.CrossRefPubMedGoogle Scholar
  40. 40.
    Domchek SM, Jhaveri K, Patil S, et al. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. Cancer. 2013;119(7):1344-1348.CrossRefPubMedGoogle Scholar
  41. 41.
    Minion LE, Coleman RL, Alvarez RD, Herzog TJ. Endpoints in clinical trials: what do patients consider important? A survey of the Ovarian Cancer National Alliance. Gynecol Oncol. 2016;140(2):193-198.CrossRefPubMedGoogle Scholar
  42. 42.
    Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proc Natl Acad Sci U S A. 2011;108(44):18032-18037.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Society of Surgical Oncology 2017

Authors and Affiliations

  • Charlotte Gamble
    • 1
  • Laura J. Havrilesky
    • 1
    • 2
    • 3
  • Evan R. Myers
    • 1
    • 3
  • Junzo P. Chino
    • 3
    • 5
  • Scott Hollenbeck
    • 4
  • Jennifer K. Plichta
    • 3
    • 7
  • P. Kelly Marcom
    • 3
    • 6
  • E. Shelley Hwang
    • 3
    • 7
  • Noah D. Kauff
    • 1
    • 3
  • Rachel A. Greenup
    • 3
    • 7
  1. 1.Department of Obstetrics and GynecologyDuke University Medical CenterDurhamUSA
  2. 2.Division of Gynecologic OncologyDuke University Medical CenterDurhamUSA
  3. 3.Duke Cancer InstituteDurhamUSA
  4. 4.Department of General Surgery, Division of Plastics, Maxillofacial and Oral SurgeryDuke University Medical CenterDurhamUSA
  5. 5.Department of Radiation OncologyDuke University Medical CenterDurhamUSA
  6. 6.Division of Medical OncologyDuke University Medical CenterDurhamUSA
  7. 7.Department of Surgery, Division of Advanced Oncologic and Gastrointestinal SurgeryDuke University Medical CenterDurhamUSA

Personalised recommendations